

## Regulation of Uptake and Processing of the Quorum-Sensing Autoinducer AI-2 in *Escherichia coli*

Karina B. Xavier and Bonnie L. Bassler\*

Department of Molecular Biology, Princeton University, Princeton, New Jersey

Received 15 June 2004/Accepted 16 September 2004

**AI-2 is a quorum-sensing signaling molecule proposed to be involved in interspecies communication. In *Escherichia coli* and *Salmonella enterica* serovar Typhimurium, extracellular AI-2 accumulates in exponential phase, but the amount decreases drastically upon entry into stationary phase. In *S. enterica* serovar Typhimurium, the reduction in activity is due to import and processing of AI-2 by the Lsr transporter. We show that the Lsr transporter is functional in *E. coli*, and screening for mutants defective in AI-2 internalization revealed *lsrK* and *glpD*. Unlike the wild type, *lsrK* and *glpD* mutants do not activate transcription of the *lsr* operon in response to AI-2. *lsrK* encodes the AI-2 kinase, and the *lsrK* mutant fails to activate *lsr* expression because it cannot produce phospho-AI-2, which is the *lsr* operon inducer. *glpD* encodes the glycerol-3-phosphate (G3P) dehydrogenase, which is involved in glycerol and G3P metabolism. G3P accumulates in the *glpD* mutant and represses *lsr* transcription by preventing cyclic AMP (cAMP)-catabolite activator protein (CAP)-dependent activation. Dihydroxyacetone phosphate (DHAP) also accumulates in the *glpD* mutant, and DHAP represses *lsr* transcription by a cAMP-CAP-independent mechanism involving LsrR, the *lsr* operon repressor. The requirement for cAMP-CAP in *lsr* activation explains why AI-2 persists in culture fluids of bacteria grown in media containing sugars that cause catabolite repression. These findings show that, depending on the prevailing growth conditions, the amount of time that the AI-2 signal is present and, in turn, the time that a given community of bacteria remains exposed to this signal can vary greatly.**

Quorum sensing is a cell-to-cell signaling process that enables bacteria to collectively control gene expression, thereby synchronizing activities that are productive only at a high population density. This process is accomplished through the production, secretion, and detection of small chemical signals called autoinducers. Production and detection of most autoinducers are restricted to organisms in a species. In contrast, one autoinducer, designated AI-2, and its synthase, LuxS, are widely distributed in the bacterial kingdom, and AI-2 controls a variety of traits in different bacteria (18, 48, 55). These unique characteristics of AI-2 have led to the hypothesis that AI-2 is used for interspecies communication.

AI-2 was initially identified for its control of the expression of bioluminescence in the marine bacterium *Vibrio harveyi* (1). Genetic and biochemical analyses of mutants defective in AI-2 production showed that AI-2 is made from *S*-adenosylmethionine (39), which is used as a methyl donor in a variety of cellular processes which yield *S*-adenosylhomocysteine. *S*-Adenosylhomocysteine is subsequently metabolized to adenine and *S*-ribosylhomocysteine. *S*-Ribosylhomocysteine is the substrate for LuxS, which cleaves it to produce homocysteine and 4,5-dihydroxy-2,3-pentanedione (DPD). DPD cyclizes spontaneously and undergoes further rearrangements to form AI-2. The structure of AI-2 bound to the *V. harveyi* AI-2 binding protein LuxP was determined, and the results showed that *V. harveyi* AI-2 is a furanosyl borate diester, indicating that borate adds to the hydrated cyclized DPD molecule (8).

The biosynthetic pathways leading to production of DPD

have been shown to be identical in *Escherichia coli*, *Salmonella enterica* serovar Typhimurium, *V. harveyi*, *Vibrio cholerae*, *Enterococcus faecalis*, *Neisseria meningitidis*, *Porphyromonas gingivalis*, and *Staphylococcus aureus* (39, 54). While these findings indicate that all LuxS-containing bacteria make DPD by the same metabolic pathway, it is not clear whether any bacteria besides *V. harveyi* use the furanosyl borate diester form of AI-2 or if different bacteria use a variety of rearranged species of DPD as the active AI-2 signal. Recent work with the AI-2 binding protein from *S. enterica* serovar Typhimurium suggests that the latter is true. Specifically, analysis of the *S. enterica* serovar Typhimurium AI-2 bound to the *S. enterica* serovar Typhimurium AI-2 binding protein LsrB showed that it does not contain boron. Rather, cyclized, hydrated DPD, with a stereochemistry different from that of *V. harveyi* AI-2, is the active ligand for *S. enterica* serovar Typhimurium (35).

Since the discovery of AI-2 in *V. harveyi*, other organisms have been shown to use AI-2 to regulate genes specifying diverse functions, such as genes encoding virulence factors in *Actinobacillus actinomycetemcomitans* (19, 20), enterohemorrhagic *E. coli* (EHEC) O157:H7 (43), *P. gingivalis* (7, 9), *Streptococcus pyogenes* (32), *V. cholerae* (29, 34, 57), and *Vibrio vulnificus* (27); motility in *Campylobacter jejuni* (15), EHEC O157:H7, and enteropathogenic *E. coli* O127:H6 (21, 45); cell division in *E. coli* W3110 and EHEC O157:H7 (13, 44); antibiotic production in *Photobacterium luminescens* (14); biofilm formation and carbohydrate metabolism in *Streptococcus gordonii* (33); and an AI-2 ATP binding cassette (ABC)-type transporter in *S. enterica* serovar Typhimurium (50). These reports indicate that different bacteria use AI-2 to control an assortment of niche-specific genes. However, the mechanism of AI-2 detection and the signal transduction pathway linking

\* Corresponding author. Mailing address: Department of Molecular Biology, Princeton University, Princeton, NJ 08544-1014. Phone: (609) 258-2857. Fax: (609) 258-6175. E-mail: bbassler@molbio.princeton.edu.




FIG. 1. Model for AI-2 production and internalization in *S. enterica* serovar Typhimurium. (A) AI-2 (pentagons) is synthesized by LuxS and accumulates extracellularly. AI-2 is internalized by the Lsr ABC-type transporter, and internalized AI-2 is phosphorylated by the LsrK kinase. Phospho-AI-2 is the inducer of transcription of the *lsr* operon and is proposed to act by binding to LsrR, the repressor of the *lsr* operon, inactivating it. LsrF and LsrG are required for further processing of internalized AI-2. The dotted lines indicate hypothetical processes. (B) *E. coli* *b1513* operon is homologous to the *S. enterica* serovar Typhimurium *lsr* operon. *lsr* gene designations are indicated under the annotations. *b1516* (*lsrB*) encodes the periplasmic AI-2 binding protein. *b1514* (*lsrC*) and *b1515* (*lsrD*) encode the channel proteins, and *b1513* (*lsrA*) encodes the ATPase that provides energy for AI-2 transport. *b1517* (*lsrF*) is similar to genes specifying aldolases, and *b1518* (*lsrG*) encodes a protein with an unknown function. There is no *lsrE* in the *E. coli* *lsr* operon. *ydeV* and *ydeW* encode proteins homologous to the AI-2 kinase LsrK and the *lsr* repressor LsrR, respectively.

AI-2 detection to target gene expression have been established only in *V. harveyi*, *V. cholerae*, and *S. enterica* serovar Typhimurium.

Surprisingly, unlike canonical autoinducers which accumulate in the stationary phase, in most bacteria examined, extracellular AI-2 activity peaks in mid- to late exponential phase and declines precipitously in stationary phase. In *S. enterica* serovar Typhimurium the rapid disappearance of AI-2 is a consequence of its import by an ABC transporter designated the Lsr transporter (*luxS* regulated). The *lsr* operon contains seven genes, *lsrACDBFGE*, and its transcription is activated by AI-2 (Fig. 1A) (50). The first four genes, *lsrACDB*, encode components of the AI-2 transporter apparatus. The distal genes are required for processing of AI-2 following internalization (49). Adjacent to, but transcribed divergently from the *lsr* operon is *lsrR*, which encodes a repressor of *lsr* transcription, and *lsrK*, which encodes a kinase that phosphorylates intracellular AI-2 following import (49, 50). Phosphorylation of internalized AI-2 is required for induction of transcription of the *lsr* operon, suggesting that phospho-AI-2 is the inducer of this system. It is postulated that phospho-AI-2 binds to the LsrR repressor and inactivates it and that this results in derepression of *lsr* transcription (49) (Fig. 1A).

*E. coli* has an operon that is homologous to the *S. enterica*

serovar Typhimurium *lsr* operon and is annotated the *b1513* operon (Fig. 1B). In the present work, we showed that the *b1513* operon of *E. coli* also encodes an AI-2 transporter. Additionally, a genetic screen to identify *E. coli* mutants impaired in the ability to import AI-2 from culture fluids revealed that mutants blocked in glycerol or glycerol 3-phosphate (G3P) metabolism are unable to induce *lsr* transcription and thus cannot internalize AI-2. We propose that repression of *lsr* transcription is caused by the accumulation of cytoplasmic G3P and dihydroxyacetone phosphate (DHAP). G3P represses the *lsr* operon via catabolite repression, whereas DHAP causes repression by an LsrR-dependent and catabolite repression-independent route. We suggest that DHAP inhibits binding of phospho-AI-2 to LsrR and that this prevents induction of transcription of the *lsr* operon.

## MATERIALS AND METHODS

**Bacterial strains, plasmids, and media.** The strains used are listed in Table 1. Wild-type (WT) *E. coli* K-12 strain MG1655 (5) was used as the parental strain. Strains were grown in Luria-Bertani (LB) medium with shaking at 37°C. Where indicated below, medium was supplemented with carbon sources at a concentration of 0.4% (wt/vol) and/or with antibiotics at the following final concentrations: ampicillin, 100 mg liter<sup>-1</sup>; chloramphenicol, 25 mg liter<sup>-1</sup>; kanamycin, 50 mg liter<sup>-1</sup>; and tetracycline, 10 mg liter<sup>-1</sup>.

**Genetic and molecular techniques.** Generalized transduction with bacteriophage P1 was performed as described previously (41). Plasmid preparation and transformation were performed using standard protocols (38). PCRs were performed using *Taq* DNA polymerase (Boehringer Mannheim Biochemicals) except when PCR products were used for cloning. In the latter cases, *ExTaq* DNA polymerase (Takara Biochemicals) was used. Sequencing reactions were performed by the Princeton University SynSeq facility.

**Screening for *E. coli* mutants defective in AI-2 internalization.** To identify genes involved in AI-2 internalization, we screened for mutants with high levels of AI-2 activity in cell-free fluids from cultures in stationary phase. WT *E. coli* MG1655 was mutated with mini-Tn10Cm (28), and mutants were selected on LB agar plates containing chloramphenicol. Approximately 10,000 mutant colonies were ordered on grids on LB agar plates containing chloramphenicol, and following growth, aliquots were transferred to 96-well microtiter plates (Polystyrene; Costar, Corning Incorporated) containing LB medium with 30% glycerol. The plates were frozen and stored at -80°C. For screening, frozen mutants were stamped onto 96-well 0.22- $\mu$ m-pore-size filtration plates (Multiscreen-GV; MAGGV2210; Millipore) containing 150  $\mu$ l of LB medium. The cultures were grown at 37°C with shaking for 14 h. Cell-free culture fluids were collected by vacuum filtration and assayed for AI-2 activity (as described below). Mutants that had detectable AI-2 activity in their culture fluids were selected for study, and this phenotype was verified by measuring AI-2 production throughout the growth curve. The mini-Tn10Cm insertion from each candidate mutant was backcrossed into MG1655 via P1 transduction, and the AI-2 internalization phenotype was verified. The location of each transposon insertion was identified by arbitrary primed PCR (36, 37). When necessary, PCR products were purified from 1% low-melting-point agarose (SeaPlaque; FMC Bioproducts) with  $\beta$ -agarase (New England Biolabs). The transposon-chromosome fusion junctions were sequenced with primer Ec67 (Table 2).

**AI-2 activity assay.** The AI-2 activity in cell-free *E. coli* culture fluids was measured using the *V. harveyi* BB170 bioluminescence reporter assay, as described previously (1, 2). Cell-free culture fluids were prepared by filtration of liquid cultures (46, 47) or by filtration through 96-well filtration plates as described above. AI-2 activity is reported below as fold induction of light production compared with the background light obtained with the appropriate *E. coli* growth medium.

**Time course of AI-2 production.** To measure AI-2 production in *E. coli* strains during growth, overnight cultures were diluted (1:100) into 200 ml of LB medium in 2-liter Erlenmeyer flasks. Aliquots were collected at various times and used for measurement of the optical density at 600 nm (OD<sub>600</sub>), preparation of cell-free culture fluids, and preparation of cell extracts for Western blot analysis when necessary (see below). To distinguish between mutants with reduced AI-2 internalization and mutants with growth defects, the AI-2 production and growth rates of the mutants were determined. Parallel 96-well filtration plates and standard 96-well microtiter plates containing 150  $\mu$ l of LB medium and 2  $\mu$ l of

TABLE 1. *E. coli* strains used in this study

Strain	Relevant genotype	Parent strain	Source or strain construction (reference)
MG1655	Wild type		
KX11	<i>lsrK</i> ::Tn10Cm	MG1655	See text
KX17	<i>glpD</i> ::Tn10Cm	MG1655	See text
KX1200	$\Delta luxS$ ::Cm	MG1655	Primers Ec39 and Ec40 for deletion
KX1108	$\Delta lacZYA$	MG1655	Primers Ec42 and Ec43 for deletion, Cm removed by flip out (12)
KX1123	<i>lsr-lacZ</i>	KX1108	See text
KX1218	<i>lsr-lacZ</i> $\Delta luxS$ ::Cm	KX1123	$\Delta luxS$ ::Cm from strain KX1200
KX1290	<i>lsr-lacZ</i> $\Delta luxS$	KX1218	Cm removed by flip out (12)
KX1186	<i>lsr-lacZ</i> <i>lsrK</i> ::Tn10Cm	KX1123	<i>lsrK</i> ::Tn10Cm from strain KX11
KX1372	<i>lsr-lacZ</i> <i>lsrK</i> ::Tn10Cm $\Delta luxS$	KX1290	<i>lsrK</i> ::Tn10Cm from strain KX11
KX1304	<i>lsr-lacZ</i> <i>glpD</i> ::Tn10Cm	KX1123	<i>glpD</i> ::Tn10Cm from strain KX17
KX1306	<i>lsr-lacZ</i> <i>glpD</i> ::Tn10Cm $\Delta luxS$	KX1290	<i>glpD</i> ::Tn10Cm from strain KX17
KX1382	$\Delta lsrCDB$ ::Cm	MG1655	Primers Ec51 and Ec52 for deletion
KX1310	<i>lsr-lacZ</i> $\Delta glpR$ ::Cm	KX1123	Primers Ec63 and Ec64 for deletion (53)
RJ70	<i>glpF</i> ::Tn10Tet <i>glpK</i>		
KX1420	<i>lsr-lacZ</i> <i>glpK</i>	KX1123	<i>glpK</i> from strain RJ70
KX1328	<i>lsr-lacZ</i> $\Delta lsrR$ ::Kan	KX1123	Primers Ec47 and Ec48 for deletion
RD14	$\Delta cya$ ::Kan <i>crp</i> *		Winfried Boos laboratory collection
KX1481	<i>lsr-lacZ</i> $\Delta cya$ ::Kan	KX1123	$\Delta cya$ ::Kan from strain RD14
KX1468	<i>lsr-lacZ</i> $\Delta cya$ ::Kan <i>crp</i> *	KX1481	<i>crp</i> * from strain RD14
KX1483	<i>lsr-lacZ</i> $\Delta cya$ ::Kan <i>crp</i> * <i>glpD</i> ::Tn10Cm	KX1468	<i>glpD</i> ::Tn10Cm from strain KX17
KX1322	<i>lsr-lacZ</i> $\Delta lsrR$ ::Cm	KX1123	Primers Ec47 and Ec48 for deletion
KX1374	<i>lsr-lacZ</i> $\Delta lsrR$ ::Kan <i>glpD</i> ::Tn10Cm	KX1328	<i>glpD</i> ::Tn10Cm from strain KX17
KX1536	<i>lsr-lacZ</i> <i>glpD</i> ::Tn10Cm <i>glpK</i>	KX1304	<i>glpK</i> from strain RJ70
KX1541	<i>lsr-lacZ</i> <i>glpD</i> ::Tn10Cm <i>glpK</i> $\Delta cya$ ::Kan <i>crp</i> *	KX1483	<i>glpK</i> from strain RJ70
DLT242	<i>gldA</i> ::Tn10Tet $\Delta(glpFKX)$	MC4100	(52)
KX1537	<i>lsr-lacZ</i> <i>gldA</i> ::Tn10Tet $\Delta(glpFKX)$	KX1123	<i>gldA</i> ::Tn10Tet $\Delta(glpFKX)$ from strain DLT242
KX1543	<i>lsr-lacZ</i> $\Delta cya$ ::Kan <i>crp</i> * <i>gldA</i> ::Tn10Tet $\Delta(glpFKX)$	KX1468	<i>gldA</i> ::Tn10Tet $\Delta(glpFKX)$ from strain DLT242
KX1547	<i>lsr-lacZ</i> <i>gldA</i> ::Tn10Tet $\Delta glpK$ <i>glpD</i> ::Tn10Cm	KX1537	<i>glpD</i> ::Tn10Cm from strain KX17
KX1549	<i>lsr-lacZ</i> $\Delta cya$ ::Kan <i>crp</i> * <i>gldA</i> ::Tn10Tet $\Delta glpK$ <i>glpD</i> ::Tn10Cm	KX1543	<i>glpD</i> ::Tn10Cm from strain KX17

the overnight cultures of the candidate mutants were incubated for various times at 37°C with shaking. The cultures from the filter plates were used to prepare cell-free culture fluids for AI-2 activity assays, and the cultures in the standard plates were used for measurement of the optical density with a Wallac Victor<sup>2</sup> model 1420 multilabel counter.

**Western blot analysis.** To measure LuxS protein in *E. coli*, culture aliquots were collected throughout growth, and the OD<sub>600</sub> was used to normalize the number of cells per milliliter. Culture volumes equivalent to 1 ml with an OD<sub>600</sub> of 1 were harvested by centrifugation. The cells were resuspended in 250  $\mu$ l of water and frozen at -80°C. To 100  $\mu$ l of frozen cells, 50  $\mu$ l of 3 $\times$  sodium dodecyl sulfate-polyacrylamide electrophoresis sample buffer was added, and samples were boiled for 10 min. Identical samples (20  $\mu$ l) were loaded into two separate

sodium dodecyl sulfate-12.5% polyacrylamide gel electrophoresis gels. One gel was used for protein visualization, and the other was used for Western transfer and analysis with anti-LuxS polyclonal antiserum (25). Anti-rabbit immunoglobulin G-alkaline phosphatase conjugate (Promega) was used for visualization.

**Construction of a chromosomal single-copy *lsr-lacZ* transcriptional fusion.** An *lsr-lacZ* transcriptional fusion was constructed by the method described by Hand and Silhavy (23). The *lsr* promoter region, containing the *lsrA* (*b1513*)-*lsrR* (*yldeW*) intergenic region and about 200 nucleotides 5' and 3' of this region, was PCR amplified from the *E. coli* chromosome with primers Ec68 and Ec69 (Table 2). The resulting 721-bp PCR product was purified, digested with EcoRI and BamHI, and ligated to the EcoRI and BamHI sites located immediately upstream of the promoterless *lacZ* gene in pRS415 (23). The plasmid obtained was

TABLE 2. Primers used in this study

Primer	Oligonucleotide sequence
Ec39.....	TCAGAAAATTTTAAAAAAATTACCGGAGGTGGCTAAATGGTGTAGGCTGGAGCTGCTTC
Ec40.....	TCATTTGAACTGGCTTTTTC AATTAATTGTGAAGATAGTTTACTGACTACATATGAATATCCTCCTTAGT
Ec42.....	GAGCGCAACGCAATTAATGTGAGTTAGCTCACTCATTAGGCACCCAGGCGTGTAGGCTGGAGCTGCTTC
Ec43.....	GCTGAACCTGTAGGCCTGATAAGCGCAGCGTATCAGGCAATTTTTATAATCATATGAATATCCTCCTTAGT
Ec47.....	GTGAAGAATGAATTATGACAATCAACGATTCGGCAATTCAGAACAGGGAGTGTAGGCTGGAGCTGCTTC
Ec48.....	CTCTATACGTTCTCCATCATTTCCCGTAATAAGGTCATGCAAATTTAACTCATATGAATATCCTCCTTAGT
Ec51.....	CTGAAGTTTATTCAGAACACCGTGAAATCACGGCACTGCTGGCGGTGGTGTAGGCTGGAGCTGCTTC
Ec52.....	GAAATCGTATTTGCCGATATTCTCTTTGTTGAATATCACGCGCTCCGGTAACATATGAATATCCTCCTTAGT
Ec63.....	CCAGGGATTTATAAATGAAACAAACACAACGTCACAACGGTATTATCGAAGTGTAGGCTGGAGCTGCTTC
Ec64.....	AAATACCTGGCGCGTTTTGGTCTGACGTGGGAAGCCGTGCAGGATCAGCACATATGAATATCCTCCTTAGT
Ec68.....	GCGAATTCGAGTTTCATATCCAGACGCCTTC
Ec69.....	GCGGGATCCGAACTGGCGTTAATCTGACGTAG
Ec67.....	CTGCCTCCAGAGCCTG




FIG. 2. Extracellular AI-2 accumulation in *E. coli*. WT *E. coli* strain MG1655 was inoculated into LB medium at time zero, and at various times aliquots were taken. (A) Cell growth was monitored by measuring the optical density (●), and AI-2 activity in cell-free culture fluids was measured using the *V. harveyi* bioluminescence assay (■). (B) LuxS production was determined by Western blotting using anti-LuxS antibodies.

electroporated into KX1108 ( $\Delta lacZYA$ ), and subsequently the *lsr-lacZ* fusion was recombined onto  $\lambda$ RS45 and integrated into the  $\lambda$  attachment (*att*) site of KX1108.

**Construction of deletion and insertion mutants.** Deletions were constructed by methods described previously (12). Antibiotic resistance cassettes were amplified by PCR from plasmids pKD3 (chloramphenicol) and pKD4 (kanamycin), using primers with 20 bp of homology to the flanking regions of the antibiotic cassette and 50 bp of homology to the flanking regions of the gene to be deleted. The primers used for each deletion are listed in Table 2. *glpK* mutants were constructed by transducing the *glpF::Tn10Tet* insertion from strain RJ70 to the relevant strains. This *glpF::Tn10Tet* insertion is polar on *glpK*, and consequently, strains with this insertion are unable to phosphorylate glycerol and cannot grow on glycerol as the sole carbon source (53). Importantly, the insertion in *glpF* does not affect glycerol transport at the glycerol concentrations used in this work (31). P1 transduction from strain DLT242 [*gldA::Tn10Tet*  $\Delta$ (*glpFKX*)] was used to construct the *gldA* and *gldA glpK* mutants (52). *gldA* is cotransducible with *glpFKX*. Therefore, *gldA* single mutants were obtained by selecting for tetracycline resistance followed by screening for growth on glycerol minimal medium, whereas *gldA glpFKX* double mutants were obtained by selection for tetracycline resistance followed by screening for the inability to grow on glycerol as the sole source of carbon.

**Construction of the  $\Delta cya::Kan$  *crp*\* strains.** To construct strains insensitive to catabolite repression, we used a P1 lysate from strain RD14 (Winfried Boos laboratory collection) which contains a *cya* deletion linked to kanamycin and the *crp*\* mutation encoding a derivative of catabolite activator protein (CAP) that acts as a transcriptional activator in the absence of cyclic AMP (cAMP). These two mutations were transferred to the desired strains by two sequential P1 transductions. First,  $\Delta cya::Kan$  was transduced with P1 to KX1123 (*lsr-lacZ*) by using selection for Kan<sup>r</sup> (obtaining strain KX1481). Because a  $\Delta cya::Kan$  mutant cannot grow on glycerol, in a second step we used the P1 lysate from RD14 to transduce the *crp*\* mutation into KX1481 (*lsr-lacZ*  $\Delta cya::Kan$ ) by selecting for growth on M63 medium containing glycerol and kanamycin. This second step produced strain KX1468 (*lsr-lacZ*  $\Delta cya::Kan$  *crp*\*). Whenever the *glpD::Tn10Cm* insertion was transduced into a strain containing the  $\Delta cya::Kan$  *crp*\* mutations, we verified that the resulting strain retained the ability to grow on maltose minimal medium to ensure that the *crp*\* mutation had been maintained.

**$\beta$ -Galactosidase assays.** Overnight cultures of *E. coli* were diluted 1:100 into fresh LB medium and grown with aeration at 37°C for 5 h or as indicated below. Cells from 1 ml of culture were harvested and resuspended in 1 ml of Z buffer for determination of the  $\beta$ -galactosidase activity as described previously (42).  $\beta$ -Galactosidase activity was calculated as follows: (OD<sub>420</sub> minute<sup>-1</sup>  $\times$  dilution factor)/OD<sub>600</sub>. All assays were performed in triplicate. The error bars in the graphs below indicate the standard deviations.

## RESULTS

**Identification of genes involved in AI-2 internalization in *E. coli*.** When *E. coli* was grown in LB medium, AI-2 activity increased during exponential growth and began to decline during the transition from exponential phase to stationary phase. By early stationary phase there was no detectable AI-2 in *E. coli* culture fluids (Fig. 2A). Antibodies to the LuxS protein showed that despite drastically reduced levels of extracellular AI-2, the AI-2 synthase LuxS was present even during late stationary phase (Fig. 2B). Thus, we could not account for the reduced AI-2 activity through obvious effects on LuxS production. Consistent with this finding, studies with *S. enterica* serovar Typhimurium have shown that transcription and translation of *luxS* remain constant throughout all phases of growth (3).

To identify genes that influence the levels of AI-2 in cell-free culture fluids, we constructed a library of random *Tn10Cm* transposon insertions in *E. coli* MG1655. Using an AI-2-specific reporter strain of *V. harveyi*, we screened the insertion mutants to identify those with AI-2 activity in the culture fluid in late stationary phase. Mutants with dramatic growth defects were discarded because we reasoned that slow growth would




FIG. 3. Extracellular AI-2 accumulation in *E. coli* mutants. AI-2 activity in cell-free culture fluids was measured using the *V. harveyi* bioluminescence bioassay. The following strains were analyzed: MG1655 (WT), KX17 (*glpD*), and KX11 (*lsrK*, annotated *ydeV*).

delay both extracellular AI-2 accumulation and disappearance. Ten thousand mutants were assayed, and two mutants were selected for study. The phenotypes of these two mutants are compared to that of the WT strain in Fig. 3. The transposon-chromosome fusion junctions of the selected mutants were amplified by PCR, and the insertion sites were identified by DNA sequence analysis coupled with BLAST database analysis.

One transposon insertion that resulted in a mutant defective in AI-2 internalization was in *glpD*, the gene encoding the enzyme G3P dehydrogenase (GlpD), which catalyzes the aerobic oxidation of G3P to DHAP. This mutant displays a modest growth defect (data not shown). Nonetheless, it was chosen for further study because the defect in AI-2 internalization was more severe than would be expected to be due to the slightly lower growth rate. The second mutant had an insertion in *ydeV*, which encodes the homolog of the *S. enterica* serovar Typhimurium gene which we previously designated *lsrK*.

**LsrK and the Lsr transporter are required for AI-2 internalization and processing in *E. coli*.** Finding *ydeV* in our screen of *E. coli* motivated us to examine the function and regulation of this gene, as well as the function and regulation of the other genes of the *b1513* operon (homologous to the *S. enterica* serovar Typhimurium *lsr* operon) (Fig. 1B). To do this, we inserted a single copy of a *b1513-lacZ* promoter fusion at the *att* site of the *E. coli* chromosome and studied its regulation. Transcription of the *b1513* operon in *E. coli* was induced in the WT strain but not in a  $\Delta luxS$  mutant (Fig. 4). Addition of in vitro-synthesized AI-2 restored *b1513* transcription in the  $\Delta luxS$  mutant (data not shown). In the WT strain, expression of *b1513-lacZ* was maximal at 5 h of growth, which corresponded to maximal AI-2 accumulation in culture fluids, and mutants with mutations in transporter components (*lsrCDB*) were defective in internalization of AI-2 (Fig. 5).

The *E. coli ydeV* mutant displayed only low-level transcription of *b1513* both in the presence and in the absence of *luxS* (Fig. 4). In the *S. enterica* serovar Typhimurium *lsrK* mutant, transcription of the *lsr* operon was similarly reduced, and this




FIG. 4. Expression of the *lsr* operon in *E. coli* mutants in the presence and absence of *luxS*. The  $\beta$ -galactosidase activity of the *lsr-lacZ* (*b1513-lacZ*) fusion was determined in strains KX1123 (WT), KX1218 (*luxS*), KX1186 (*lsrK*), KX1372 (*lsrK luxS*), KX1304 (*glpD*), and KX1306 (*glpD luxS*) after 5 h of growth.

resulted in a low level of production of the Lsr transporter, which caused AI-2 accumulation and persistence in the extracellular medium. Figure 5 shows that this was true for the *E. coli ydeV* (*lsrK*) mutant. Therefore, with respect to regulation of expression of the operon and AI-2 uptake, the *E. coli b1513* (*lsrCDB*) and *ydeV* (*lsrK*) mutants have phenotypes identical to those of the *S. enterica* serovar Typhimurium *lsr* operon and *lsrK* mutants, respectively. We concluded that these functions are analogous in *E. coli* and *S. enterica* serovar Typhimurium, and therefore we designated the *b1513* operon of *E. coli* the *lsr* operon and the *E. coli ydeV* gene *lsrK* (Fig. 1B).

It was initially puzzling that of the *lsr* genes, only *lsrK* was identified in the present screen because the *lsrACDB* genes are also required to efficiently remove AI-2 from culture fluids. However, we determined that *E. coli lsrCDB* mutants but not *lsrK* mutants are capable of removing AI-2 from culture fluids, albeit significantly more slowly than the WT strain (Fig. 5). We propose that the slow AI-2 internalization occurs through some low-affinity transport system (49). Specifically, WT *E. coli*




FIG. 5. Extracellular AI-2 accumulation in *E. coli* Lsr transporter mutants. AI-2 activity in cell-free culture fluids was measured using the *V. harveyi* bioluminescence bioassay. The following strains were analyzed: MG1655 (WT), KX1382 (*lsrCDB*), and KX11 (*lsrK*).

internalizes most of the AI-2 by 6 h, whereas an *lsrCDB* mutant requires 10 h for the equivalent internalization (Fig. 5) and the *lsrK* mutant internalizes little or no AI-2 even after 12 h (Fig. 3 and 5). Our determinations of AI-2 activity in the culture fluids of the transposon insertion mutants were made after 14 h growth. Therefore, we believe that the persistence of AI-2 for a longer period of time in culture fluids of the *lsrK* mutant than in culture fluids of the *lsrCDB* mutants accounted for our identification of *lsrK* but not *lsrACDB* in this experimental setup.

Interestingly, similar to the phenotype of an *E. coli lsrK* mutant, *lsr-lacZ* remained repressed in a *glpD* mutant irrespective of the presence of *luxS* (Fig. 4). We assumed that reduced *lsr* operon transcription in the *glpD* mutant resulted in an inability to assemble the Lsr transporter and to import AI-2, and this explains why AI-2 persisted in the cell-free culture fluids.

***glp* regulon and *lsr* repression.** *GlpD* is the enzyme responsible for funneling G3P to the glycolytic pathway, and it is essential for glycerol and G3P metabolism under aerobic conditions (Fig. 6) (30, 31). *E. coli* has another G3P dehydrogenase encoded by *glpA*, but this enzyme is functional only under anaerobic conditions (30, 31). *glpD* is a member of the *glp* regulon, which is under transcriptional control of the *GlpR* repressor. Specifically, the *glp* regulon is repressed by *GlpR* in the absence of glycerol. Growth on glycerol causes derepression of the regulon, and glycerol is imported via the *GlpF* permease. Internalized glycerol is phosphorylated to G3P by the glycerol kinase *GlpK*, and G3P is subsequently oxidized to DHAP by *GlpD* (Fig. 6). To understand why the *lsr* operon is repressed in a *glpD* mutant, we examined the expression of the *lsr* operon in *E. coli* in the presence of glycerol and G3P (Table 3). Addition of glycerol and G3P to the LB growth medium caused 21- and 5-fold repression of *lsr-lacZ* transcription, respectively. Glycerol probably caused greater *lsr* repression than G3P caused because glycerol is internalized more efficiently than G3P. Addition of either glycerol or G3P to the *glpD* mutant did not alter *lsr* expression. However, this result was anticipated because transcription of the *lsr* operon was already fully repressed in the *glpD* mutant (Table 3).

Curiously, there is a putative *GlpR* binding site immediately downstream of the predicted *lsrR* promoter, encoding the repressor of the *lsr* operon. This observation suggested that *GlpR* could directly regulate the *lsr* operon by regulating *lsrR* expression. We found that this cannot be the case, however, because transcription of the *lsr* promoter, as measured by the *lsr-lacZ* fusion, was similar in WT *E. coli* and the  $\Delta$ *glpR* mutant and, furthermore, *lsr* repression by glycerol and G3P occurred in the  $\Delta$ *glpR* mutant (Table 3). In fact, repression of *lsr* expression by glycerol and G3P was slightly greater in the  $\Delta$ *glpR* mutant than in WT *E. coli*. We reasoned that because the *glp* regulon was derepressed in the  $\Delta$ *glpR* mutant, the glycerol and G3P transport systems were expressed at higher levels in the  $\Delta$ *glpR* mutant than in the WT strain. Thus, compared to the WT strain, increased uptake of the two substrates occurred in the  $\Delta$ *glpR* mutant, which in turn promoted increased repression of *lsr* expression.

**Both glycerol and G3P repress *lsr* transcription.** Glycerol represses the maltose (*mal*) uptake and utilization regulon via catabolite repression (16, 17), and we suspected that glycerol




FIG. 6. Aerobic glycerol and G3P metabolism in *E. coli*. Glycerol enters the cytoplasm through the glycerol facilitator (*GlpF*) and can be phosphorylated to G3P by the glycerol kinase (*GlpK*). In the presence of oxygen, G3P is oxidized by the G3P dehydrogenase (*GlpD*) to DHAP, which is further metabolized through the glycolytic pathway. Intracellular glycerol can also be oxidized to DHA by *GldA*. DHA is converted to DHAP by the DHA kinase (*DhaK*), which uses *DhaM* as a phosphoryl donor protein. G3P is required for phospholipid biosynthesis, and in the absence of extracellular glycerol, intracellular G3P is formed from DHAP by the G3P synthase (*GpsA*). In a *glpD* mutant G3P accumulates due to conversion of glycerol to G3P by *GlpK*. Intracellular G3P accumulation prevents cAMP formation by inhibiting the stimulation of adenylate cyclase via phospho-EIIA<sup>Glc</sup> (16). As a consequence, cAMP-CAP activation of the *lsr* operon is inhibited significantly. G3P accumulation also inhibits *GpsA* by a negative feedback mechanism, which leads to DHAP accumulation. We hypothesize that DHAP represses the *lsr* operon by a mechanism independent of cAMP-CAP that involves *LsrR*, the repressor of the *lsr* operon. The solid lines indicate enzymatic reactions, the dashed lines indicate regulatory interactions, and the dotted lines indicate the newly proposed regulatory interaction resulting from this work. FAD, flavin adenine dinucleotide; FADH<sub>2</sub>, reduced flavin adenine dinucleotide.

could similarly repress *lsr* and, in turn, AI-2 uptake and utilization. The *mal* regulon of *E. coli* is a typical catabolite-sensitive regulon. Cyclic AMP and the catabolite activator protein (cAMP-CAP) control expression of several members of this regulon (6). Glycerol-mediated repression of the *mal* regulon occurs when glycerol is converted to G3P via phosphorylation by the glycerol kinase *GlpK*, but it does not occur in a *glpK*

TABLE 3. *lsr-lacZ* expression in *E. coli* grown in LB medium with glycerol or G3P

Genotype	$\beta$ -Galactosidase activity (u) <sup>a</sup>			Fold repression with:	
	LB medium	LB medium + glycerol	LB medium + G3P	Glycerol	G3P
WT	1,071 $\pm$ 66	50 $\pm$ 1	214 $\pm$ 2	21	5
<i>glpD</i>	41 $\pm$ 1	39 $\pm$ 1	49 $\pm$ 1	1	1
<i>glpR</i>	752 $\pm$ 68	26 $\pm$ 1	134 $\pm$ 4	29	6
<i>glpK</i>	885 $\pm$ 52	274 $\pm$ 2	171 $\pm$ 5	3	5

<sup>a</sup> The  $\beta$ -galactosidase activities of the *lsr-lacZ* fusion were measured in strains KX1123 (WT), KX1304 (*glpD*), KX1310 (*glpR*), and KX1420 (*glpK*) following 5 h of growth in LB medium or LB medium containing 0.4% glycerol or 0.4% G3P.




FIG. 7. Effect of catabolite repression and the GldA pathway on the expression of *lsr* transcription. The  $\beta$ -galactosidase activity of the *lsr-lacZ* fusion was measured in strains KX1123 (WT), KX1481 ( $\Delta cya$ ), KX1468 ( $\Delta cya$   $crp^*$ ), KX1304 (*glpD*), KX1483 (*glpD*  $\Delta cya$   $crp^*$ ), KX1536 (*glpD* *glpK*), KX1541 (*glpD* *glpK* *cya*  $crp^*$ ), KX1547 (*glpD* *glpK* *gldA*), and KX1549 (*glpD* *glpK* *gldA* *cya*  $crp^*$ ) after 5 h of growth in LB medium.

mutant (Fig. 6). Importantly, *mal* gene transcription is repressed following exogenous addition of G3P to either the *glpK* or *glpD* mutant (i.e., even when G3P cannot be converted to DHAP [Fig. 6]). Thus, G3P is the sole mediator of glycerol repression of the *mal* regulon, and neither glycerol, metabolites derived from glycerol, nor metabolites derived from G3P can substitute for G3P (16).

We investigated whether it was glycerol or G3P that was responsible for repression of *lsr* transcription by measuring *lsr* transcription in a *glpK* mutant. Repression by glycerol decreased from 21-fold in the WT strain to 3-fold in the *glpK* mutant (Table 3). Mutation of *glpK* did not alter the ability of G3P to repress transcription of the *lsr* operon, as fivefold repression occurred in the WT strain and the *glpK* mutant (Table 3). These results show that the majority of the repression of *lsr* transcription that occurs when *E. coli* is grown in glycerol is due to G3P and not to glycerol. Interestingly, while glycerol causes no repression of *mal* genes in the *glpK* mutant, glycerol consistently causes low-level (threefold) repression of *lsr* transcription in the *glpK* mutant. We verified that this low-level *lsr* repression was not due to the slight increase in pH that occurs during growth in LB medium by growing cells in buffered LB medium with or without glycerol (data not shown). Thus, we suggest that G3P causes repression of the *lsr* operon but, unlike regulation of *mal* gene expression, additionally, glycerol itself or some product derived from glycerol also causes partial repression of *lsr* expression.

**G3P represses *lsr* transcription via catabolite repression.** G3P-mediated repression of transcription of the *mal* genes in *E. coli* requires the cAMP-CAP system (16, 17). Double mutants harboring a deletion in the adenylate cyclase gene (*cya*) and a gain-of-function mutation in the CAP gene (*crp^\**) are not sensitive to cAMP-CAP repression because the *crp^\** mutation allows CAP to act as a transcriptional activator in the absence of cAMP. In a  $\Delta cya$   $crp^*$  genetic background, G3P does not repress transcription of *mal* regulon genes (16, 17). There is a CAP binding site upstream of the *lsr* operon, and consistent with this, *lsr* was repressed in the  $\Delta cya$  single mutant but not in the  $\Delta cya$   $crp^*$  double mutant (Fig. 7), showing that *lsr* transcription depends on cAMP and CAP. To examine whether G3P interferes with cAMP-CAP activation of the *lsr* operon, we added G3P to the  $\Delta cya$   $crp^*$  double mutant (Table

4). No G3P repression of *lsr* expression occurred in the  $\Delta cya$   $crp^*$  double mutant. Therefore, G3P repression occurs exclusively through prevention of cAMP-CAP-dependent activation of the *lsr* operon. Surprisingly, however, repression of the *lsr* operon did occur in a  $\Delta cya$   $crp^*$  mutant when glycerol was added (Table 4). Specifically, glycerol caused 21-fold repression in the WT strain and 8-fold repression in the  $\Delta cya$   $crp^*$  double mutant. Thus, repression by glycerol is partially independent of cAMP-CAP.

**Repression of *lsr* in a *glpD* mutant is caused by cAMP-CAP-dependent and -independent mechanisms.** We wondered if G3P-mediated inhibition of cAMP-CAP-dependent activation of *lsr* expression could explain our initial observation that the *lsr* operon is repressed in a *glpD* mutant. Specifically, in a *glpD* mutant, G3P metabolism is blocked and intracellular G3P accumulates (Fig. 6) (11, 56). We considered the possibility that in the *glpD* mutant increased intracellular G3P levels could lead to inhibition of cAMP-CAP-dependent activation of *lsr*. If this occurs, G3P repression of *lsr* should not occur in a *glpD*  $\Delta cya$   $crp^*$  triple mutant. Figure 7 shows that *lsr* expression was repressed 15-fold in the *glpD* mutant but only 7-fold in the *glpD*  $\Delta cya$   $crp^*$  triple mutant. These results show that G3P acting through cAMP-CAP accounts for a portion of the repression of the *lsr* operon observed in a *glpD* mutant, but an additional cAMP-CAP-independent mechanism must also be involved. To support this idea, we assayed the *lsr* expression phenotypes of the *glpD* *glpK* double mutant and the *glpD* *glpK* *cya*  $crp^*$  quadruple mutant. In these mutants, G3P was not produced and glycerol accumulated (Fig. 6). The *lsr* operon remained

TABLE 4. *lsr-lacZ* expression in *E. coli* mutants insensitive to catabolite repression grown in LB medium with G3P or glycerol

Genotype	$\beta$ -Galactosidase activity (u) <sup>a</sup>			Fold repression with:	
	LB medium	LB medium + G3P	LB medium + glycerol	G3P	Glycerol
WT	1,071 $\pm$ 66	226 $\pm$ 2	50 $\pm$ 1	5	21
<i>cya</i> $crp^*$	1,094 $\pm$ 46	886 $\pm$ 12	137 $\pm$ 8	1	8

<sup>a</sup> The  $\beta$ -galactosidase activities of the *lsr-lacZ* fusion were measured in strains KX1123 (WT) and KX1468 ( $\Delta cya$   $crp^*$ ) following 5 h of growth in LB medium or LB medium containing 0.4% G3P or 0.4% glycerol.

repressed in a *glpD glpK* double mutant both in the presence and in the absence of a functional cAMP-CAP system (Fig. 7). These results, along with those shown in Table 4, verified that G3P accumulation cannot be the exclusive cause of *lsr* repression in a *glpD* mutant.

All of the results described above suggest that glycerol and/or a metabolite made from glycerol that is not G3P causes partial repression of *lsr* expression in the *glpD* mutant. A candidate for the metabolite is DHAP (Fig. 6). The GldA enzyme oxidizes glycerol to dihydroxyacetone (DHA) (26, 51, 52), which can subsequently be phosphorylated to DHAP by the DHA kinase, DhaK (22, 40) (Fig. 6). Although this route for glycerol metabolism is not sufficient to sustain growth on glycerol, it does allow conversion of glycerol to DHAP in a *glpK* mutant. To investigate the possibility that DHA or DHAP is involved in *lsr* repression, we transduced a *gldA* mutation into the *glpD glpK* double mutant and the *glpD glpK Δcya crp\** quadruple mutant. In both cases, inactivation of *gldA* restored expression of the *lsr* operon to WT levels (Fig. 7). We concluded that the *lsr* repression observed in *glpD* mutants unable to produce G3P is caused by the metabolism of glycerol via the GldA-DhaK pathway. We suggest that DHAP accumulates in the *glpD* single mutant and that it is the metabolite responsible for the cAMP-CAP-independent repression of the *lsr* operon. Accumulation of DHAP in a *glpD* mutant is expected because G3P accumulates and G3P feedback inhibits GpsA, the enzyme that catalyzes the conversion of DHAP to G3P (4, 10) (Fig. 6) (see Discussion).

We noted that in contrast to the results described above, the threefold repression of *lsr* expression that occurred in a *glpK* mutant grown on glycerol (Table 3) was likely not due to glycerol metabolism to DHAP through the GldA-DhaK pathway because this repression also occurred in a *glpK gldA* double mutant (data not shown). Rather, we believe that addition of extracellular glycerol does not induce the GldA-DhaK pathway when *glpD* is intact, and therefore, under the conditions used for the experiments whose results are shown in Table 3, glycerol itself appears to be able to cause a low level of *lsr* repression.

#### Repression of *lsr* expression in a *glpD* mutant requires LsrR.

We wondered whether repression of the *lsr* operon in the *glpD* mutant requires the known *lsr* regulator, LsrR. To test this, we measured the *lsr* expression and AI-2 activity phenotypes of the *glpD* and *lsrR* single mutants and the *glpD lsrR* double mutant. *lsr* operon expression was repressed in a *glpD* mutant (Fig. 8A), causing a reduction in AI-2 import, and consequently, AI-2 persisted in culture fluids (Fig. 8B). In contrast, inactivation of *lsrR* caused high-level expression of *lsr* (Fig. 8A), resulting in rapid AI-2 import and a dramatic loss of AI-2 activity from culture fluids (Fig. 8B). The repression of *lsr* transcription caused by mutation of *glpD* was partially relieved by mutation of *lsrR* (Fig. 8A). Importantly, this partial relief of transcriptional repression allowed AI-2 internalization that was as efficient as that in the *lsrR* single mutant (Fig. 8B). This result demonstrates that in terms of AI-2 transport, *lsrR* is epistatic to *glpD*, suggesting that LsrR is involved in the mechanism by which mutation of *glpD* causes *lsr* repression.




FIG. 8. *lsrR* is epistatic to *glpD*. (A)  $\beta$ -Galactosidase activity of the *lsr-lacZ* fusion in strains KX1123 (WT), KX1304 (*glpD*), KX1328 (*lsrR*), and KX1374 (*glpD lsrR*) at different times during growth in LB medium. (B) AI-2 activity in cell-free culture fluids of strains MG1655 (WT), KX17 (*glpD*), KX1328 (*lsrR*), and KX1374 (*glpD lsrR*) as determined by the *V. harveyi* bioluminescence bioassay.

## DISCUSSION

*E. coli* grown in LB medium releases and accumulates AI-2 in culture fluids during exponential growth. Maximal AI-2 activity is observed at the transition from exponential phase to stationary growth phase, after which the AI-2 activity rapidly disappears from the culture fluids. In *S. enterica* serovar Typhimurium, the disappearance of AI-2 from culture fluids is due to AI-2 uptake by the Lsr transport system, which is induced by the presence of AI-2. *E. coli* possesses an operon (previously designated the *b1513* operon) homologous to the *S. enterica* serovar Typhimurium *lsr* operon. Transcriptional analysis of the *E. coli lsr-lacZ* fusion showed that AI-2 induces the expression of the *lsr* operon, and examination of mutants showed that the *lsr* operon is required for import and processing of AI-2. We concluded that the *E. coli lsr* operon functions analogously to the *lsr* operon of *S. enterica* serovar Typhimurium.

A screen for *E. coli* mutants defective in AI-2 internalization



allowed us to identify *lsrK* and *glpD*. In these mutants, the *lsr* operon is uninducible, and so they display only low-level expression of the *lsr* operon both in the presence and in the absence of AI-2. We suspect that repression of transcription of the *lsr* operon in *lsrK* and *glpD* mutants results in their inability to assemble the Lsr transport apparatus, which in turn impairs their ability to internalize AI-2.

The *E. coli* *lsrK* homolog (annotated *ydeV*) is 79% identical to the *S. enterica* serovar Typhimurium *lsrK* gene. We previously showed that *S. enterica* serovar Typhimurium *lsrK* mutants do not internalize AI-2 like the WT does, and the *lsr* operon is not inducible by AI-2. Our characterization of the *E. coli* *lsrK* mutant showed it has phenotypes identical to those of the *S. enterica* serovar Typhimurium *lsrK* mutant (Fig. 3 and 4), suggesting that these mutants are functionally equivalent. We have shown explicitly that in *S. enterica* serovar Typhimurium LsrK phosphorylates AI-2. Therefore, *lsrK* mutants accumulate extracellular AI-2 because they cannot sequester AI-2 (as phospho-AI-2) in the cell. We propose that in *E. coli*, *lsrK* mutants do not induce *lsr* transcription in response to AI-2 because phospho-AI-2 is the antirepressor of *lsr* transcription, and this molecule is not produced in *lsrK* mutants.

A mutation in *glpD* causes a defect in AI-2 internalization, and, similar to the *lsrK* mutant, the *glpD* mutant does not induce transcription of *lsr* in response to AI-2. In a *glpD* mutant, G3P metabolism is blocked, and intracellular G3P accumulates as a consequence of phospholipid metabolism (11, 56). Our results show that the *lsr* operon is repressed by G3P via a cAMP-CAP-dependent mechanism. However, catabolite repression by G3P is not sufficient to explain *lsr* repression in the *glpD* mutant since this repression is not fully relieved by introduction of the  $\Delta$ *cya crp*\* double mutation or by preventing G3P accumulation through introduction of a *glpK* mutation. Thus, an additional G3P-independent, cAMP-CAP-independent mechanism of *lsr* transcriptional repression must also be involved. When G3P metabolism is blocked, in addition to accumulation of G3P, DHAP can accumulate because G3P feedback inhibits GpsA-catalyzed conversion of DHAP to G3P (4, 10) (Fig. 6). Thus, increased G3P levels can promote increased DHAP levels. Therefore, the repression that we observed in the *glpD* mutant could have been due to DHAP or a metabolite derived from DHAP. Consistent with this hypothesis, when we eliminated glycerol metabolism to DHAP in the *glpK glpD* double mutant via inactivation of the GldA-DhaK pathway, repression of *lsr* was fully relieved.

Our results show that LsrR is required for the repression that we observed in the *glpD* mutant (Fig. 8). We propose that the cAMP-CAP-independent mechanism of *lsr* repression involves the interaction of DHAP (or possibly a metabolite derived from it) with the LsrR protein. Consistent with this, exogenous addition of DHA (which is converted to DHAP intracellularly) also causes LsrR-dependent *lsr* repression (data not shown). DHAP could act as an anti-inducer of the *lsr* operon by inhibiting the binding of phospho-AI-2 to LsrR, which could cause LsrR to remain locked in its active, repressing state. To validate this hypothesis, we are currently purifying LsrR for binding and competition assays with phospho-AI-2 and DHAP.

Understanding the physiology underlying the Glp-Lsr connection requires further analysis of the fate of internalized

phospho-AI-2. In *S. enterica* serovar Typhimurium, the LsrF and LsrG proteins are involved in modifying phospho-AI-2, but the specific reactions that each carries out have not been characterized, nor are the products of these modifications known. It is possible that one of these products is DHAP since pentose phosphates are often converted to DHAP in order to be channeled to the glycolytic pathway for further metabolism. We are currently focusing on characterizing these biochemical reactions in both *E. coli* and *S. enterica* serovar Typhimurium.

Interestingly, the *glpD* mutant phenotype more closely mimics the *lsrK* mutant phenotype than the *lsrCDB* transporter mutant phenotypes. In transporter mutants, the presence of AI-2 in culture fluids is prolonged; however, AI-2 eventually disappears, presumably due to internalization by some low-affinity transporter. In contrast, AI-2 persists in culture fluids indefinitely in *lsrK* mutants, and we attribute this to a lack of phosphorylation or sequestration of internalized AI-2. Specifically, in an *lsrK* mutant, any AI-2 internalized by a secondary transporter does not get phosphorylated, and thus it cannot be sequestered. However, we do not believe that sequestration (i.e., AI-2 phosphorylation) is affected in the *glpD* mutant because in an *lsrR glpD* double mutant AI-2 is rapidly imported and remains sequestered (Fig. 8B), whereas in an *lsrR lsrK* double mutant extracellular AI-2 accumulates to wild-type levels (data not shown). We propose instead that the defect in AI-2 internalization is more severe in a *glpD* mutant than in the *lsr* transporter mutants because the secondary AI-2 transporter(s) is also subject to G3P catabolite repression in the *glpD* mutant. Consistent with this idea, in a *glpD*  $\Delta$ *cya crp*\* triple mutant, although the *lsr* transporter is greatly repressed, most of the AI-2 is internalized by 10 h (data not shown).

Previous reports showed that high levels of extracellular AI-2 are detected when *E. coli* is grown on glucose, whereas no AI-2 can be detected in cell-free culture fluids when *E. coli* is grown in the absence of glucose (46). The present results explain both of these observations. First, in the presence of glucose, the *lsr* operon is not transcribed due to catabolite repression. Thus, AI-2 cannot be imported, and it accumulates in cell-free culture fluids. Second, in the absence of glucose, AI-2 is produced, but its presence is extremely transient due to rapid internalization by the Lsr transporter. DeLisa et al. (13) used DNA microarrays to identify genes controlled by AI-2 in *E. coli*. These experiments were performed with *E. coli* grown in the presence of glucose, and catabolite repression of transcription of the *lsr* operon by glucose could explain why none of the *lsr* genes was identified in this study. Similarly, it was reported that glucose, by an unknown mechanism, caused AI-2 to persist in cell-free culture fluids of *E. coli* (24). We show here that this mechanism is in fact cAMP-CAP-mediated repression of AI-2 import primarily through the Lsr apparatus.

At present, we do not understand the benefit that enteric bacteria derive from producing and releasing AI-2, only to internalize it later. Further work is necessary to determine if the physiological function of AI-2 as a signal in these bacteria is more significant under conditions in which AI-2 is imported and processed or under conditions in which the *lsr* transporter is not produced and AI-2 accumulates in the medium. In the first case, internalization of AI-2 could be used as a mechanism to terminate AI-2-controlled behaviors in *E. coli* or in other

species in the vicinity. Alternatively, AI-2 internalization and modification could be used to transform the AI-2 signal into a different cytoplasmic signal. In the second case, in which the genes encoding the Lsr transport apparatus are repressed, cells that encounter AI-2 are exposed to this signal for a longer period of time than when the transporter is produced. Prolonged exposure to the signal could be useful for controlling other AI-2-dependent behaviors. There could be AI-2 receptors on the surface that, rather than internalize the signal, transduce the AI-2 sensory information to the cytoplasm to alter target gene expression. Studying the *lsrK* and *lsrR* mutants, in which the *lsr* operon is constitutively repressed and constitutively derepressed, respectively, should enable us to examine the role of AI-2 under these two conditions.

#### ACKNOWLEDGMENTS

This work was supported by NIH grant 5R01 GM065859 and by NSF grant MCB-0343821. K.B.X. was supported by Praxis XXI, Portugal award BPD-22064-99.

We are grateful to members of the Bassler lab for critical discussions of this work and to members of the Silhavy group for advice on experiments. We thank W. Boos for generously supplying strains and for insightful advice.

#### REFERENCES

- Bassler, B. L., M. Wright, R. E. Showalter, and M. R. Silverman. 1993. Intercellular signalling in *Vibrio harveyi*: sequence and function of genes regulating expression of luminescence. *Mol. Microbiol.* **9**:773–786.
- Bassler, B. L., M. Wright, and M. R. Silverman. 1994. Multiple signalling systems controlling expression of luminescence in *Vibrio harveyi*: sequence and function of genes encoding a second sensory pathway. *Mol. Microbiol.* **13**:273–286.
- Beeston, A. L., and M. G. Surette. 2002. *pfs*-dependent regulation of autoinducer 2 production in *Salmonella enterica* serovar Typhimurium. *J. Bacteriol.* **184**:3450–3456.
- Bell, R. M., and J. E. Cronan, Jr. 1975. Mutants of *Escherichia coli* defective in membrane phospholipid synthesis. Phenotypic suppression of *sn*-glycerol-3-phosphate acyltransferase Km mutants by loss of feedback inhibition of the biosynthetic *sn*-glycerol-3-phosphate dehydrogenase. *J. Biol. Chem.* **250**:7153–7158.
- Blattner, F. R., G. Plunkett III, C. A. Bloch, N. T. Perna, V. Burland, M. Riley, J. Collado-Vides, J. D. Glasner, C. K. Rode, G. F. Mayhew, J. Gregor, N. W. Davis, H. A. Kirkpatrick, M. A. Goeden, D. J. Rose, B. Mau, and Y. Shao. 1997. The complete genome sequence of *Escherichia coli* K-12. *Science* **277**:1453–1474.
- Boos, W., and H. Shuman. 1998. Maltose/maltodextrin system of *Escherichia coli*: transport, metabolism, and regulation. *Microbiol. Mol. Biol. Rev.* **62**:204–229.
- Burgess, N. A., D. F. Kirke, P. Williams, K. Winzer, K. R. Hardie, N. L. Meyers, J. Aduse-Opoku, M. A. Curtis, and M. Camara. 2002. LuxS-dependent quorum sensing in *Porphyromonas gingivalis* modulates protease and haemagglutinin activities but is not essential for virulence. *Microbiology* **148**:763–772.
- Chen, X., S. Schauder, N. Potier, A. Van Dorsselaer, I. Pelczar, B. L. Bassler, and F. M. Hughson. 2002. Structural identification of a bacterial quorum-sensing signal containing boron. *Nature* **415**:545–549.
- Chung, W. O., Y. Park, R. J. Lamont, R. McNab, B. Barbieri, and D. R. Demuth. 2001. Signaling system in *Porphyromonas gingivalis* based on a LuxS protein. *J. Bacteriol.* **183**:3903–3909.
- Clark, D., V. Lightner, R. Edgar, P. Modrich, J. E. Cronan, Jr., and R. M. Bell. 1980. Regulation of phospholipid biosynthesis in *Escherichia coli*. Cloning of the structural gene for the biosynthetic *sn*-glycerol-3-phosphate dehydrogenase. *J. Biol. Chem.* **255**:714–717.
- Cronan, J. E., Jr., and C. O. Rock. 1996. Biosynthesis of membrane lipids, p. 612–636. *In* F. C. Neidhardt, R. Curtiss III, J. L. Ingraham, E. C. C. Lin, K. B. Low, B. Magasanik, W. S. Reznikoff, M. Riley, M. Schaechter, and H. E. Umbarger (ed.), *Escherichia coli* and *Salmonella*: cellular and molecular biology, 2nd ed., vol. 1. American Society for Microbiology, Washington, D.C.
- Datsenko, K. A., and B. L. Wanner. 2000. One-step inactivation of chromosomal genes in *Escherichia coli* K-12 using PCR products. *Proc. Natl. Acad. Sci. USA* **97**:6640–6645.
- DeLisa, M. P., C. F. Wu, L. Wang, J. J. Valdes, and W. E. Bentley. 2001. DNA microarray-based identification of genes controlled by autoinducer 2-stimulated quorum sensing in *Escherichia coli*. *J. Bacteriol.* **183**:5239–5247.
- Derzelle, S., E. Duchaud, F. Kunst, A. Danchin, and P. Bertin. 2002. Identification, characterization, and regulation of a cluster of genes involved in carbapenem biosynthesis in *Photobacterium luminescens*. *Appl. Environ. Microbiol.* **68**:3780–3789.
- Elvers, K. T., and S. F. Park. 2002. Quorum sensing in *Campylobacter jejuni*: detection of a *luxS* encoded signalling molecule. *Microbiology* **148**:1475–1481.
- Eppler, T., and W. Boos. 1999. Glycerol-3-phosphate-mediated repression of *malT* in *Escherichia coli* does not require metabolism, depends on enzyme IIAGlc and is mediated by cAMP levels. *Mol. Microbiol.* **33**:1221–1231.
- Eppler, T., P. Postma, A. Schutz, U. Volker, and W. Boos. 2002. Glycerol-3-phosphate-induced catabolite repression in *Escherichia coli*. *J. Bacteriol.* **184**:3044–3052.
- Federle, M. J., and B. L. Bassler. 2003. Interspecies communication in bacteria. *J. Clin. Investig.* **112**:1291–1299.
- Fong, K. P., W. O. Chung, R. J. Lamont, and D. R. Demuth. 2001. Intra- and interspecies regulation of gene expression by *Actinobacillus actinomycetemcomitans* LuxS. *Infect. Immun.* **69**:7625–7634.
- Fong, K. P., L. Gao, and D. R. Demuth. 2003. *luxS* and *arcB* control aerobic growth of *Actinobacillus actinomycetemcomitans* under iron limitation. *Infect. Immun.* **71**:298–308.
- Giron, J. A., A. G. Torres, E. Freer, and J. B. Kaper. 2002. The flagella of enteropathogenic *Escherichia coli* mediate adherence to epithelial cells. *Mol. Microbiol.* **44**:361–379.
- Gutknecht, R., R. Beutler, L. F. Garcia-Alles, U. Baumann, and B. Erni. 2001. The dihydroxyacetone kinase of *Escherichia coli* utilizes a phospho-protein instead of ATP as phosphoryl donor. *EMBO J.* **20**:2480–2486.
- Hand, N. J., and T. J. Silhavy. 2000. A practical guide to the construction and use of *lac* fusions in *Escherichia coli*. *Methods Enzymol.* **326**:11–35.
- Hardie, K. R., C. Cooksley, A. D. Green, and K. Winzer. 2003. Autoinducer 2 activity in *Escherichia coli* culture supernatants can be actively reduced despite maintenance of an active synthase, LuxS. *Microbiology* **149**:715–728.
- Henke, J. M., and B. L. Bassler. 2004. Quorum sensing regulates type III secretion in *Vibrio harveyi* and *Vibrio parahaemolyticus*. *J. Bacteriol.* **186**:3794–3805.
- Jin, R. Z., J. C. Tang, and E. C. Lin. 1983. Experimental evolution of a novel pathway for glycerol dissimilation in *Escherichia coli*. *J. Mol. Evol.* **19**:429–436.
- Kim, S. Y., S. E. Lee, Y. R. Kim, C. M. Kim, P. Y. Ryu, H. E. Choy, S. S. Chung, and J. H. Rhee. 2003. Regulation of *Vibrio vulnificus* virulence by the LuxS quorum-sensing system. *Mol. Microbiol.* **48**:1647–1664.
- Kleckner, N., J. Bender, and S. Gottesman. 1991. Uses of transposons with emphasis on *Tn10*. *Methods Enzymol.* **204**:139–180.
- Lenz, D. H., K. C. Mok, B. N. Lilley, R. V. Kulkarni, N. S. Wingreen, and B. L. Bassler. 2004. The small RNA chaperone Hfq and multiple small RNAs control quorum sensing in *Vibrio harveyi* and *Vibrio cholerae*. *Cell* **118**:69–82.
- Lin, E. C. 1976. Glycerol dissimilation and its regulation in bacteria. *Annu. Rev. Microbiol.* **30**:535–578.
- Lin, E. C. 1996. Dissimilatory pathways for sugars, polyols, and carboxylates, p. 307–342. *In* F. C. Neidhardt, R. Curtiss III, J. L. Ingraham, E. C. C. Lin, K. B. Low, B. Magasanik, W. S. Reznikoff, M. Riley, M. Schaechter, and H. E. Umbarger (ed.), *Escherichia coli* and *Salmonella*: cellular and molecular biology, 2nd ed., vol. 1. American Society for Microbiology, Washington, D.C.
- Lyon, W. R., J. C. Madden, J. C. Levin, J. L. Stein, and M. G. Caparon. 2001. Mutation of *luxS* affects growth and virulence factor expression in *Streptococcus pyogenes*. *Mol. Microbiol.* **42**:145–157.
- McNab, R., S. K. Ford, A. El-Sabaeny, B. Barbieri, G. S. Cook, and R. J. Lamont. 2003. LuxS-based signaling in *Streptococcus gordonii*: autoinducer 2 controls carbohydrate metabolism and biofilm formation with *Porphyromonas gingivalis*. *J. Bacteriol.* **185**:274–284.
- Miller, M. B., K. Skorupski, D. H. Lenz, R. K. Taylor, and B. L. Bassler. 2002. Parallel quorum sensing systems converge to regulate virulence in *Vibrio cholerae*. *Cell* **110**:303–314.
- Miller, S. T., K. B. Xavier, S. R. Campagna, M. E. Taga, M. F. Semmelhack, B. L. Bassler, and F. M. Hughson. 2004. *Salmonella typhimurium* recognizes a chemically distinct form of the bacterial quorum sensing signal AI-2. *Mol. Cell* **15**:677–687.
- O'Toole, G. A., L. A. Pratt, P. I. Watnick, D. K. Newman, V. B. Weaver, and R. Kolter. 1999. Genetic approaches to study of biofilms. *Methods Enzymol.* **310**:91–109.
- Pratt, L. A., and R. Kolter. 1998. Genetic analysis of *Escherichia coli* biofilm formation: roles of flagella, motility, chemotaxis and type I pili. *Mol. Microbiol.* **30**:285–293.
- Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. *Molecular cloning: a laboratory manual*, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
- Schauder, S., K. Shokat, M. G. Surette, and B. L. Bassler. 2001. The LuxS family of bacterial autoinducers: biosynthesis of a novel quorum-sensing signal molecule. *Mol. Microbiol.* **41**:463–476.
- Siebold, C., L. F. Garcia-Alles, B. Erni, and U. Baumann. 2003. A mecha-

- nism of covalent substrate binding in the X-ray structure of subunit K of the *Escherichia coli* dihydroxyacetone kinase. Proc. Natl. Acad. Sci. USA **100**: 8188–8192.
41. Silhavy, T. J., M. L. Berman, and L. W. Enquist. 1984. Experiments with gene fusions. Cold Spring Harbor Press, Cold Spring Harbor, N.Y.
  42. Slauch, J. M., and T. J. Silhavy. 1991. *cis*-acting *ompF* mutations that result in OmpR-dependent constitutive expression. J. Bacteriol. **173**:4039–4048.
  43. Sperandio, V., J. L. Mellies, W. Nguyen, S. Shin, and J. B. Kaper. 1999. Quorum sensing controls expression of the type III secretion gene transcription and protein secretion in enterohemorrhagic and enteropathogenic *Escherichia coli*. Proc. Natl. Acad. Sci. USA **96**:15196–15201.
  44. Sperandio, V., A. G. Torres, J. A. Giron, and J. B. Kaper. 2001. Quorum sensing is a global regulatory mechanism in enterohemorrhagic *Escherichia coli* O157:H7. J. Bacteriol. **183**:5187–5197.
  45. Sperandio, V., A. G. Torres, and J. B. Kaper. 2002. Quorum sensing *Escherichia coli* regulators B and C (QseBC): a novel two-component regulatory system involved in the regulation of flagella and motility by quorum sensing in *E. coli*. Mol. Microbiol. **43**:809–821.
  46. Surette, M. G., and B. L. Bassler. 1998. Quorum sensing in *Escherichia coli* and *Salmonella typhimurium*. Proc. Natl. Acad. Sci. USA **95**:7046–7050.
  47. Surette, M. G., and B. L. Bassler. 1999. Regulation of autoinducer production in *Salmonella typhimurium*. Mol. Microbiol. **31**:585–595.
  48. Surette, M. G., M. B. Miller, and B. L. Bassler. 1999. Quorum sensing in *Escherichia coli*, *Salmonella typhimurium*, and *Vibrio harveyi*: a new family of genes responsible for autoinducer production. Proc. Natl. Acad. Sci. USA **96**:1639–1644.
  49. Taga, M. E., S. T. Miller, and B. L. Bassler. 2003. Lsr-mediated transport and processing of AI-2 in *Salmonella typhimurium*. Mol. Microbiol. **50**:1411–1427.
  50. Taga, M. E., J. L. Semmelhack, and B. L. Bassler. 2001. The LuxS-dependent autoinducer AI-2 controls the expression of an ABC transporter that functions in AI-2 uptake in *Salmonella typhimurium*. Mol. Microbiol. **42**:777–793.
  51. Tang, J. C., E. J. St. Martin, and E. C. Lin. 1982. Derepression of an NAD-linked dehydrogenase that serves an *Escherichia coli* mutant for growth on glycerol. J. Bacteriol. **152**:1001–1007.
  52. Truniger, V., and W. Boos. 1994. Mapping and cloning of *gldA*, the structural gene of the *Escherichia coli* glycerol dehydrogenase. J. Bacteriol. **176**:1796–1800.
  53. Truniger, V., W. Boos, and G. Sweet. 1992. Molecular analysis of the *glpFKX* regions of *Escherichia coli* and *Shigella flexneri*. J. Bacteriol. **174**:6981–6991.
  54. Winzer, K., K. R. Hardie, N. Burgess, N. Doherty, D. Kirke, M. T. Holden, R. Linforth, K. A. Cornell, A. J. Taylor, P. J. Hill, and P. Williams. 2002. LuxS: its role in central metabolism and the in vitro synthesis of 4-hydroxy-5-methyl-3(2H)-furanone. Microbiology **148**:909–922.
  55. Xavier, K. B., and B. L. Bassler. 2003. LuxS quorum sensing: more than just a numbers game. Curr. Opin. Microbiol. **6**:191–197.
  56. Yang, B., and T. J. Larson. 1998. Multiple promoters are responsible for transcription of the *glpEGR* operon of *Escherichia coli* K-12. Biochim. Biophys. Acta **1396**:114–126.
  57. Zhu, J., M. B. Miller, R. E. Vance, M. Dziejman, B. L. Bassler, and J. J. Mekalanos. 2002. Quorum-sensing regulators control virulence gene expression in *Vibrio cholerae*. Proc. Natl. Acad. Sci. USA **99**:3129–3134.